Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility - Seite 3

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary ²¹²Pb generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," “look forward to," "target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things: the Company’s belief that as a Current Good Manufacturing Practice (cGMP) compliant facility, it intends to utilize the facility to manufacture clinical supply of high quality ²⁰³Pb-labeled tumor-specific peptides to visualize and diagnose tumors, and ²¹²Pb-labeled radiopharmaceuticals to treat target tumors with targeted alpha therapies; the Company’s expectation that with three on-site cGMP suites at the facility, it will have the capacity to meet future clinical trial and commercial demands at major cancer treatment centers throughout the Northeastern United States (U.S.); the Company’s belief that it has the infrastructure and personnel to support production of the Company’s radiopharmaceuticals, all within the vicinity of the patients it hopes to impact; the Company’s expectation that the facility will be capable of operating in compliance with Parts 212 and 211 of Title 21 of the Code of Federal Regulations (CFR); the Company’s commitment to make its targeted alpha-particle therapies available to patients in critical need and build on the Company’s strategic expansion as it looks to establish facilities in proximity to major treatment hubs in the U.S.; the Company’s expectation that the acquisition of the facility much earlier than initially planned will allow it to move forward more quickly to deliver clinical and, If approved for commercialization, commercial doses; the Company anticipates that its ²⁰³Pb-labelled peptides will be regulated under Part 212 of Title 21 of the CFR; the Company anticipates that its ²¹²Pb-labelled peptides will be regulated under Part 211 of Title 21 of the CFR; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting peptides provide the opportunity to personalize treatment and optimize patient outcomes; the Company's expectation that its "theranostic" approach enables the ability to see specific tumors and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments; the Company's clinical development plans and the expected timing thereof; the potential functionality, capabilities, and benefits of the Company's product candidates and the potential application of these product candidates for other disease indications; the Company's expectations, beliefs, intentions, and strategies regarding the future; and other statements that are not historical fact.